

### INSTRUCTIONS FOR MORPHINE EQUIVALENT DAILY DOSE (MEDD)

Translate the dose and route of each of the opioids the patient has received over the last 24 hours to parenteral morphine equivalent using a standard conversion table (see below).

**MEDD initial:** It is the 24hr opioid dose before the physician meets with the patient. (Using the conversion table found online which has the MEDD factors). i.e midnight-midnight.

**MEDD final:** The final 24 hrs opioid dosage that the patient receives.

•Discharged: Take the last complete 24hr period the patient received opioid dosage before discharge.

•Death: Take the last complete 24hr period that the patient was alive for and use that as the final MEDD dosage.

### MORPHINE EQUIVALENT DAILY DOSE (MEDD) CONVERSION TABLE

MEDICATION	ROUTE	MEDD_FACTOR	MEDICATION	ROUTE	MEDD_FACTOR
BUPRENORPHINE	TD	0.1	METHADONE	IT	240
CODEINE	IM	0.1	METHADONE	IV	8
CODEINE	PO	0.05	METHADONE	PO	4
CODEINE	R	0.05	METHADONE	R	4
CODEINE	SC	0.1	METHADONE	SC	8
DIAMORPHINE	PO	0.65	MORPHINE	EP	3
DIAMORPHINE	SC	1.3	MORPHINE	IT	30
DIAMORPHONE	EP	3.9	MORPHINE	IM	1
DIAMORPHONE	IT	39	MORPHINE	IV	1
FENTANYL	EP	0.3	MORPHINE	PO	0.4
FENTANYL	IT	3	MORPHINE	R	0.4
FENTANYL	PO	0.05	MORPHINE	SC	1
FENTANYL	SL	0.05	OXYCODONE	PO	0.63
FENTANYL	IV	0.1	OXYCODONE	SC	1.5
FENTANYL	SC	0.1	PROPOXYPHENE	IM	0.167
FENTANYL	TD	0.1	PROPOXYPHENE	IV	0.167
HYDROCODONE	PO	0.4	PROPOXYPHENE	PO	0.08
HYDROMORPHINE	IM	5	PROPOXYPHENE	R	0.08
HYDROMORPHINE	IV	5	PROPOXYPHENE	SC	0.167
HYDROMORPHINE	PO	2	PROPOXYPHENE	TD	0.167
HYDROMORPHINE	SC	5	SUFENTANIL	SC	1
HYDROMORPHINE	EP	15	SUFENTANIL	IV	1
HYDROMORPHINE	IT	150	SUFENTANIL	PO	0.5
LEVO-DROMORAN	SC	5	SUFENTANIL	SL	0.5
MEPERIDINE	EP	0.3	TRAMADOL	PO	0.05
MEPERIDINE	IT	3	TRAMADOL	SC	0.1
MEPERIDINE	IM	0.1			
MEPERIDINE	IV	0.1			
MEPERIDINE	PO	0.05			
MEPERIDINE	SC	0.1			
METHADONE	EP	24			

Note:

1. MEDD calculation: [DOSE] × [MEDD\_FACTOR]
2. Abbreviation list

PO	Oral
IM	Intramuscular
IV	Intravenous
SC	Subcutaneous
SL	Sublingual
R	Rectal
EP	Epidural
IT	Intrathecal
TD	Transdermal

### References:

Bruera E, Lawlor P, Watanabe S, Turner K, Hanson J. The effects of opioid rotation (OR), dose ratio (DR) on pain control and cognition in patients (P) with cancer pain. Presented at the A.S.C.O. meeting in Denver, CO May 20, 1997. Proceedings of ASCO. 1997; 16(212):62a

Charrois T, Lindsay MA, Bruera E. Utilizing a morphine equivalent daily dose for comparison of opioid use in two palliative care units in Canada. Presented at the 12th International Congress on Care of the Terminally Ill, Montreal, PQ September 13-17, 1998. J Palliat Care 1998; 14(3):117

Gagnon B, **Bruera E**. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage 1999; 18(2):120-25

Lawlor P, Pereira J, **Bruera E**. Dose Ratios Among Different Opioids: Underlying Issues and an Update on the Use of the Equianalgesic Table. In: Topics in Palliative Care Volume 5, Bruera E,

Portenoy RK (eds.) Oxford University Press, New York, NY 2001; 247-276

Lawlor PG, Quan H, Daeninck P, Hanson J, **Bruera E**. Dose Ration of Oral to Subcutaneous Hydromorphone in Advanced Cancer Patients. Presented at 12th International Symposium – Supportive Care in Cancer. MASCC and ISOO, Washington, DC, March 23-25, 2000.

Lawlor PG, Daeninck P, Doyle J, Quan H, Hanson, J, **Bruera E**. Dose ratio of oral to subcutaneous morphine in the treatment of cancer pain. American Pain Society, Ft. Lauderdale, Florida, October 21-24, 1999.

Lawlor P, Fan D, Hanson J, Bruera E. Equianalgesic conversion dose ratio of morphine (M) to hydromorphone (HM) in patients with cancer pain. Presented at the 11th International Congress on Care of the Terminally Ill. Montreal, PQ, September 7-11, 1996

Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 1997; 72(1,2):79-85

Lawlor PG, Turner KS, Hanson J, Bruera ED. Dose ratio between morphine and methadone in patients with cancer pain. Cancer 1998; 82(6):1167-73

Pereira J, Bruera E, Watanabe S, Belzile M, Hanson J. Opioid rotation in patients with cancer pain: a retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Presented at the 6th Canadian Palliative Care Conference “Setting our Sails, Advancing Care” Halifax, NS Oct. 15-17, 1995

Pereira J, Lawlor P, Vigano A, Dorgan M, **Bruera E**. Equianalgesic Dose Ratios for Opioids: A Critical Review and proposals for long-term dosing. *J Pain Symp Management* 2001; 22 (2): 672-687

Ripamonti C, De Conno F, Groff L, Belzile M, Pereira J, Hanson J, Bruera E. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: Comparison of two clinical experiences. *Ann Oncology* 1998; 9:79-83

Sittl R, Likar R, Poulsen-Nautrup B. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. *Clin Ther.* 2005;27:225–237.